Tom 3, Nr 1 (2010)
SPRAWOZDANIA, KOMUNIKATY
Opublikowany online: 2010-03-19
Wyświetlenia strony
402
Wyświetlenia/pobrania artykułu
1648
Sprawozdanie z XIX Regionalnego Zjazdu Międzynarodowego Towarzystwa Przetaczania Krwi (ISBT) oraz z obrad Grupy Roboczej ds. Zakażeń Przenoszonych przez Krew ISBT, Kair, Egipt, 21-25 marca 2009 roku
Journal of Transfusion Medicine 2010;3(1):27-34.
Streszczenie
Brak
Referencje
- Allain JP. infection in the Mediterranean basin and Europe. Vox Sang. 2009; 96(supl. 1): 17.
- Ekiaby Magdy E.l., Allain J-P, Lelie N. Hepatitis B virus DNA and surface antigen particle concentration of ultra-sensitive nucleic acid screening tests in HBsAg carriers. Vox Sang. 2009; 96(supl. 1): 17.
- Grabarczyk P, Garniri P, Brojer E, et al. Polimorphism of Hepatitis B wirus from first time blond donors with HBsAg in Poland. Vox Sang. 2009; 96(supl. 1): 18.
- Meldal B, Mojaar N, Barnes I, et al. A new Hepatitis B virus subtype D6 in Tunisian blood donors. Vox Sang. 2009; 96(supl. 1): 18.
- Busch MP, Kleinman SH. Hepatitis C infection: recent insights relevant to transfusion safety. Vox Sang. 2009; 96(supl. 1): 22.
- Busch MP, Kleinman SH. Hepatitis C infection: recent insights relevant to transfusion safety. ISBT Science Series. 2009; 4(1): 72–79.
- Rios M. Climate change and vector-borne viral diseases potentially transmitted by transfusion. ISBT Science Series. 2009; 4(1): 87–94.
- Leiby D, Nguyen M, Goff T, et al. Shifting the focus of malria deferrals:time for a new paradigm. Vox Sang. 2009; 96(supl. 1): 38.
- Assal A, Auger F, Corbi C, et al. Trypanasoma cruzi detection and quantification by real-time PCR. Vox Sang. 2009; 96(supl. 1): 39.
- Burger R. Emerging pathogens and possible threats to blood services. ISBT Science Series; Vox Sang. 2009; 4: 121.
- Burger R. Emerging pathogens and possible threats to blood services. Vox Sang. 2009; 96(supl. 1): 51.
- Sambri V, Cavrini F, et al. D’Angelo E. The outbreak of West Nile virus infection in Northern Italy: an additional new risk for the safety of blood and organ donation. Vox Sang. 2009; 96(supl. 1): 52.
- Kleinman S, Drimmelen AA. J., Lelie P.N., Busch M.P. Minipool Nat HIV-1 breakthrough transmission cases and probability of interdiction current small pool or individual-donation Nat screening systems. Vox Sang. 2009; 96(supl. 1): 53.
- Piron M, Romero A, Cosamitiana M, et al. HTLV-I/II prevalance in at-risk blood donors from Central and South America in A non-endemic area (Catalonia, Spain). Vox Sang. 2009; 96(supl. 1): 54.
- Schmidt M, Mayr-Wohlfart U, Kai M, et al. Infectivity of B19 positive blood products. Vox Sang. 2009; 96(supl. 1): 54.
- Kopacz A, Grabarczyk P, Sulkowska E, et al. The results of look back and trace back procedures for HBV DNA positive/ /HBsAg negative donors identified in Poland. Vox Sang. 2009; 96(supl. 1): 15.
- Belkacemi M. Prevalence of HIV in blood donors in the department of Sidi Bel Abbes in the democtratic and popular Algerian Republik. Vox Sang. 2009; 96(supl. 1): 104.
- Durro V, Korrqi A, Qyra M, et al. Epidemiology of transfusion-transmitted infections in multi transfused patients in Albania. Vox Sang. 2009; 96(supl. 1): 106.
- Eita N. Prevalence of HCV and HBV infections among blood donors in Dakahilia, Egypt. Vox Sang. 2009; 96(supl. 1): 106.
- Gamlath PM. G.R. The Incidence and trends of HBsAg, anti HCV, anti HIV I et II, antibodies to Treponemia Palladium and slide test for malaria parasite in Sri Lankan blood donations. Vox Sang. 2009; 96(supl. 1): 107.
- Jovanovic P. Levicnik Stecinar S. Prevalence of Anti-HTLVI/II in Slovenian blood donors and the impact on blood screening. Vox Sang. 2009; 96(supl. 1): 109.
- Kocovska E, Timova T, Momiroska T, et al. The prevalence of anti-HCV positive in blood donors in Clinic HospitalTetovo. Vox Sang. 2009; 96(supl. 1): 91.
- Ghiazza P, Demarin G, Demarchi G, et al. Analytical and technical performances evaluation on Procleix Tigris System for NAT screening in Italy. Vox Sang. 2009; 96(supl. 1): 90.
- Glauser A, Hardegger K, Gottschalk J, et al. Four parameter NAT screening by taqscreen MPX with Cobas S201 in Switzerland: validation, implementation and first experiences. Vox Sang. 2009; 96(supl. 1): 107.
- Queiros L, Teixeria A, Coelho G. Performance evaluation of a new fully automated HTLV-I/HTLV-II assay in Portuguese blood donors. Vox Sang. 2009; 96(supl. 1): 111.
- Queiros L, Teixeria A, Coelho G, et al. Specificity of architect anti-HBC II assay in comparison to prism HBCORE Assay in Portuguese blood donors. Vox Sang. 2009; 96(supl. 1): 86.
- Vucetic D, Trkuljic M, Balint B, et al. Combined human immunodeficiency virus antigen-antibody assay investigation among blood donors in Serbia. Vox Sang. 2009; 96(supl. 1): 113.
- Ziermann R, Ohhashi Y, Pai A, et al. Comparative clinical evaluation of the cobas taqscreen MPX Test with the Cobas Ampliscreen HIV-1 V1.5, HCV V2.O, and HBV Tests using high risk population and seropositive specimens. Vox Sang. 2009; 96(supl. 1): 95.
- Mihaljevic I. Evaluation of the architect HCV antigen assay for use in organ and tissue donors. Vox Sang. 2009; 96(supl. 1): 24.
- Mirshafiee H, Milani S, Sharifi Z, et al. Genotype analysis of HBV and HDV in Teheran, Iran. Vox Sang. 2009; 96(supl. 1): 83.
- Grabarczyk P, Kalińska A, Sulkowska E, et al. Polymorphism and extremely high viraemia observed in parvovirus B19 diagnostic samples-potential difficulties that could be faced during B19 screening in blood donors. Vox Sang. 2009; 96(supl. 1): 108.
- Naroozi M, Shafiri Z, Gharehbaghian A. Genotyping and phylogenetic analysis of the polymerase gene of HBV in volunteer blood donors in Iran. Vox Sang. 2009; 96(supl. 1): 84.
- Neves I, Boavida M, Peres C, et al. HBV Genotypes in blood donors of Lisbon Regional Blood Centre. Vox Sang. 2009; 96(supl. 1): 84.
- Kolundzija SK. Results of testing of confirmed positive voluntary blood donors to Hepatitis C markers — two years experience. Vox Sang. 2009; 96(supl. 1): 91.
- Kourenti A, Faukitsa V, Stamoulis K, et al. The contribution of PCR to determine the anti-HCV positive blood donors and RIBA negative or indeterminate. Vox Sang. 2009; 96(supl. 1): 91.
- Di Tullio Budassi L., Di Paolo O. HTLV I/II Western Blot Assay as a complementary test for donor folow up and counselling. Vox Sang. 2009; 96(supl. 1): 104.
- Alexopoulos A, Tseliou P. Four years experience with ID NAT testing in blood donations in Southwestern Greece. Vox Sang. 2009; 96(supl. 1): 78.
- Anwar F, Abdeinaal M, Khalid H, et al. Living with NAT: our experience at King Khalid National Guard Hospital, Jeddha, Saudi Arabia. Updates on Hepatitis C (HCV). Vox Sang. 2009; 96(supl. 1): 89.
- Neves L, Boavida N, Luig F, et al. Five years experience of NAT individual donation in Lisbon regional blood centre donors. Vox Sang. 2009; 96(supl. 1): 111.
- Nograsek P, Javonovic P. Levicnik Stezinar S. Experience in NAT screening: comparison of PCR and TMA based systems. Vox Sang. 2009; 96(supl. 1): 94.
- Keil S, Gilmour D, Miklauz M, et al. Photochemical inactivation of human Hepatitis B virus using the mirasol pathogen reduction technology (PRT) system as measured by PCR. Vox Sang. 2009; 96(supl. 1): 82.
- Yokomizo T, Nirasawa H, Kai T, et al. A combination filter for prion and leucocyte reduction, its prion reduction performance in spiking test assessed by bioassay. Vox Sang. 2009; 96(supl. 1): 114.
- Gonzalez Fraile M.I., del Bianko A.I.J., Golvano Guerrero E. Occult Hepatitis B infection in blood donors: a real problem. Vox Sang. 2009; 96(supl. 1): 19.
- Lam TP. DNA detection on HBsAg non-reactive/anti HBC reactive donation samples. Vox Sang. 2009; 96(supl. 1): 83.
- Politis CP, Vrettou H, Fragatou S, et al. Prevalence of occult Hepatitis B (OBI) in thalassaemic patients in Greece: a multicentre retrospective study. Vox Sang. 2009; 96(supl. 1): 85.
